A Phase 1 Open-label, Multicenter Study Evaluating the Safety of KITE-222, an Autologous Anti-CLL-1 CAR T-cell Therapy, in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Latest Information Update: 13 Jun 2024
At a glance
- Drugs KITE-222 (Primary) ; Cyclophosphamide; Fludarabine
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Kite Pharma
- 07 Jun 2024 Status changed from active, no longer recruiting to discontinued.
- 10 Apr 2024 Planned End Date changed from 1 Jan 2039 to 1 Feb 2026.
- 10 Apr 2024 Planned primary completion date changed from 1 Oct 2024 to 1 Feb 2026.